-
1Academic Journal
Συγγραφείς: O. Yu. Ivanova, O. L. Shikhovtsova, О. Ю. Иванова, О. Л. Шиховцова
Συνεισφορές: This study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. 056-00026-24-01 (R&D Registry No. 124022300127-0)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-01 на проведение прикладных научных исследований (номер государственного учета НИР 124022300127-0).
Πηγή: Regulatory Research and Medicine Evaluation; Том 14, № 5 (2024); 590-600 ; Регуляторные исследования и экспертиза лекарственных средств; Том 14, № 5 (2024); 590-600 ; 3034-3453 ; 3034-3062 ; 10.30895/1991-2919-2024-14-5
Θεματικοί όροι: кортикостероиды, clinical trial protocol, bioequivalence studies, clinical research evaluation, locally applied and locally acting medicinal products, creams, ointments, gels, corticosteroids, протокол клинического исследования, исследования биоэквивалентности, экспертиза клинических исследований, лекарственные препараты местного действия, кремы, мази, гели
Περιγραφή αρχείου: application/pdf
Relation: https://www.vedomostincesmp.ru/jour/article/view/715/1711; Ниязов РР, Рождественский ДА, Васильев АН, Гавришина ЕВ, Драницына МА, Куличев ДА. Регуляторные аспекты регистрации воспроизведенных и гибридных лекарственных препаратов в Евразийском экономическом союзе. Ремедиум. 2018;(7–8):6–19. https://doi.org/10.21518/1561-5936-2018-7-8-6-19; Braddy AC, Davit BM, Stier EM, Conner DR. Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products. AAPS J. 2015;17(1):121–33. https://doi.org/10.1208/s12248-014-9679-3; Lawrence XY, Li BV, eds. FDA bioequivalence standards. New York: Springer; 2014.; Lourenço D, Miranda M, Sousa JJ, Vitorino C. Therapeutic-driven framework for bioequivalence assessment of complex topical generic drug products. Int J Pharm. 2024;661:124398. https://doi.org/10.1016/j.ijpharm.2024.124398; Miranda M, Sousa JJ, Veiga F, Cardoso C, Vitorino C. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system. Eur J Pharm Sci. 2018;122:264–72. https://doi.org/10.1016/j.ejps.2018.07.011; Minghetti P, Musazzi UM, Casiraghi A, Rocco P. Old active ingredients in new medicinal products: is the regulatory path coherent with patients’ expectations? Drug Discov Today. 2020;25(8):1337–47. https://doi.org/10.1016/j.drudis.2020.05.013; Mohan V, Wairkar S. Current regulatory scenario and alternative surrogate methods to establish bioequivalence of topical generic products. J Drug Deliv Sci Technol. 2021;61(1):102090. https://doi.org/10.1016/j.jddst.2020.102090; Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, et al. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res. 2014;31(1):837–46. https://doi.org/10.1007/s11095-013-1259-1; Quartier J, Capony N, Lapteva M, Kalia YN. Cutaneous biodistribution: a high-resolution methodology to assess bioequivalence in topical skin delivery. Pharmaceutics. 2019;11(9):484. https://doi.org/10.3390/pharmaceutics11090484; Volonte P, Musazzi UM, Arnaboldi L, Ortenzi MA, Casiraghi A, Cilurzo F, et al. Equivalence assessment of creams with quali-quantitative differences in light of the EMA and FDA regulatory framework. Eur J Pharm Sci. 2024;195:106726. https://doi.org/10.1016/j.ejps.2024.106726; Krishnaiah YSR, Xu X, Rahman Z, Yang Y, Katragadda U, Lionberger R, et al. Development of performance matrix for generic product equivalence of acyclovir topical creams. Int J Pharm. 2014;475(1–2):110–22. https://doi.org/10.1016/j.ijpharm.2014.07.034; McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86(5):608–10 https://doi.org/10.1001/archderm.1962.01590110044005; Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987;123(10):1312–4. https://doi.org/10.1001/archderm.1987.01660340074023; Stoughton RB. Percutaneous absorption of drugs. Ann Rev Pharmacol Toxicol. 1989;29:55–69. https://doi.org/10.1146/annurev.pa.29.040189.000415; Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19. https://doi.org/10.1016/j.ijpharm.2010.03.017; Stoughton RB. Vasoconstrictor assay — specific application. In: Maibach HI, Surber C, eds. Topical corticosteroids. Basel: Karger; 1991. P. 42–53. https://doi.org/10.1159/000419858; Singh G. JP, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, et al. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther. 1999;66(4):346–57. https://doi.org/10.1053/cp.1999.v66.a101209; https://www.vedomostincesmp.ru/jour/article/view/715